X Chromosome-linked Inhibitor of Apoptosis Regulates Cell Death Induction by Proapoptotic Receptor Agonists

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2009 Oct 27

PMID 19854829

Citations 29

Authors

Eugene Varfolomeev

Bruno Alicke

J Michael Elliott

Kerry Zobel

Kristina West

Harvey Wong

Justin M Scheer

Avi Ashkenazi

Stephen E Gould

Wayne J Fairbrother

Domagoj Vucic

Affiliations

Soon will be listed here.

Abstract

Proapoptotic receptor agonists cause cellular demise through the activation of the extrinsic and intrinsic apoptotic pathways. Inhibitor of apoptosis (IAP) proteins block apoptosis induced by diverse stimuli. Here, we demonstrate that IAP antagonists in combination with Fas ligand (FasL) or the death receptor 5 (DR5) agonist antibody synergistically stimulate death in cancer cells and inhibit tumor growth. Single-agent activity of IAP antagonists relies on tumor necrosis factor-alpha signaling. By contrast, blockade of tumor necrosis factor-alpha does not affect the synergistic activity of IAP antagonists with FasL or DR5 agonist antibody. In most cancer cells, proapoptotic receptor agonist-induced cell death depends on amplifying the apoptotic signal via caspase-8-mediated activation of Bid and subsequent activation of the caspase-9-dependent mitochondrial apoptotic pathway. In the investigated cancer cell lines, induction of apoptosis by FasL or DR5 agonist antibody can be inhibited by knockdown of Bid. However, knockdown of X chromosome-linked IAP (XIAP) or antagonism of XIAP allows FasL or DR5 agonist antibody to induce activation of effector caspases efficiently without the need for mitochondrial amplification of the apoptotic signal and thus rescues the effect of Bid knockdown in these cells.

Citing Articles

Cell death pathways: intricate connections and disease implications.

Kist M, Vucic D EMBO J. 2021; 40(5):e106700.

PMID: 33439509 PMC: 7917554. DOI: 10.15252/embj.2020106700.

Regulation of Cell Death and Immunity by XIAP.

Jost P, Vucic D Cold Spring Harb Perspect Biol. 2019; 12(8).

PMID: 31843992 PMC: 7397824. DOI: 10.1101/cshperspect.a036426.

Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models.

Manzari M, Anderson G, Lin K, Soderquist R, Cakir M, Zhang M Sci Adv. 2019; 5(9):eaaw9162.

PMID: 31517048 PMC: 6726446. DOI: 10.1126/sciadv.aaw9162.

LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.

Yang L, Kumar B, Shen C, Zhao S, Blakaj D, Li T Mol Cancer Ther. 2019; 18(6):1025-1035.

PMID: 31015310 PMC: 6548673. DOI: 10.1158/1535-7163.MCT-18-1157.

Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins.

Finlay D, Teriete P, Vamos M, Cosford N, Vuori K F1000Res. 2017; 6:587.

PMID: 28529715 PMC: 5414821. DOI: 10.12688/f1000research.10625.1.

References

Strasser A, Jost P, Nagata S . The many roles of FAS receptor signaling in the immune system. Immunity. 2009; 30(2):180-92. PMC: 2956119. DOI: 10.1016/j.immuni.2009.01.001. View

Ashkenazi A . Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 2008; 19(3-4):325-31. DOI: 10.1016/j.cytogfr.2008.04.001. View

Varfolomeev E, Blankenship J, Wayson S, Fedorova A, Kayagaki N, Garg P . IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007; 131(4):669-81. DOI: 10.1016/j.cell.2007.10.030. View

Kaufmann T, Tai L, Ekert P, Huang D, Norris F, Lindemann R . The BH3-only protein bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell-cycle arrest. Cell. 2007; 129(2):423-33. DOI: 10.1016/j.cell.2007.03.017. View

Vince J, Wong W, Khan N, Feltham R, Chau D, Ahmed A . IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell. 2007; 131(4):682-93. DOI: 10.1016/j.cell.2007.10.037. View

LaCasse E, Mahoney D, Cheung H, Plenchette S, Baird S, Korneluk R . IAP-targeted therapies for cancer. Oncogene. 2008; 27(48):6252-75. DOI: 10.1038/onc.2008.302. View

Steller H . Mechanisms and genes of cellular suicide. Science. 1995; 267(5203):1445-9. DOI: 10.1126/science.7878463. View

Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S . Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ. 2008; 15(4):751-61. DOI: 10.1038/sj.cdd.4402306. View

Salvesen G, Duckett C . IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol. 2002; 3(6):401-10. DOI: 10.1038/nrm830. View

10.

Gaither A, Porter D, Yao Y, Borawski J, Yang G, Donovan J . A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res. 2007; 67(24):11493-8. DOI: 10.1158/0008-5472.CAN-07-5173. View

11.

Jin H, Yang R, Ross J, Fong S, Carano R, Totpal K . Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clin Cancer Res. 2008; 14(23):7733-40. DOI: 10.1158/1078-0432.CCR-08-0670. View

12.

Yin X, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B . Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature. 1999; 400(6747):886-91. DOI: 10.1038/23730. View

13.

Boatright K, Renatus M, Scott F, Sperandio S, Shin H, Pedersen I . A unified model for apical caspase activation. Mol Cell. 2003; 11(2):529-41. DOI: 10.1016/s1097-2765(03)00051-0. View

14.

Verhagen A, Ekert P, Pakusch M, Silke J, Connolly L, Reid G . Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 2000; 102(1):43-53. DOI: 10.1016/s0092-8674(00)00009-x. View

15.

Hunter A, LaCasse E, Korneluk R . The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis. 2007; 12(9):1543-68. DOI: 10.1007/s10495-007-0087-3. View

16.

Du C, Fang M, Li Y, Li L, Wang X . Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000; 102(1):33-42. DOI: 10.1016/s0092-8674(00)00008-8. View

17.

Fulda S, Wick W, Weller M, Debatin K . Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med. 2002; 8(8):808-15. DOI: 10.1038/nm735. View

18.

Flygare J, Vucic D . Development of novel drugs targeting inhibitors of apoptosis. Future Oncol. 2009; 5(2):141-4. DOI: 10.2217/14796694.5.2.141. View

19.

Zobel K, Wang L, Varfolomeev E, Franklin M, Elliott L, Wallweber H . Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chem Biol. 2006; 1(8):525-33. DOI: 10.1021/cb600276q. View

20.

Vogler M, Walczak H, Stadel D, Haas T, Genze F, Jovanovic M . Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res. 2009; 69(6):2425-34. DOI: 10.1158/0008-5472.CAN-08-2436. View